Product Information
BALZIVA 28 TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.3296 per EA under NDC 00555903458. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Apr 22, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555903458
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA076238FDA Approved
4/22/2004
TE Code
AB
On Market Since
10/16/2006
Price Statistics
The NADAC for BALZIVA 28 TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 58.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3296 per EA |
|---|---|
| All-time high | $0.9162 (Feb 11, 2015) |
| All-time low | $0.2566 (Nov 20, 2024) |
| 52-week high | $0.3471 |
| 52-week low | $0.2982 |
| Median price | $0.5100 |
| Average price | $0.5302 |
| Largest weekly change | +60.7% (May 20, 2020) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 39% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BALZIVA 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BALZIVA 28 TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.3296 per EA (NDC 00555903458), effective Sep 30, 2026.
How has the price of BALZIVA 28 TABLET changed over time?
Over the history we have for it, the NADAC for BALZIVA 28 TABLET has declined 58.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for BALZIVA 28 TABLET?
Since Nov 28, 2013, the NADAC for BALZIVA 28 TABLET has ranged from a low of $0.2566 (Nov 20, 2024) to a high of $0.9162 (Feb 11, 2015), with a median of $0.5100 per EA.
Are there cheaper alternatives to BALZIVA 28 TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NYLIA 1-35 28 TABLET, is $0.2026 per EA — about 39% below BALZIVA 28 TABLET.
Who manufactures BALZIVA 28 TABLET?
BALZIVA 28 TABLET (NDC 00555903458) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.